Molecular targeted therapy for hepatocellular carcinoma: Current and future

doi:10.3748/wjg.v19.i37.6144

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 19, Issue 37

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8528)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series, Tables (1-2) series.

Item

Count

PDF

505

HTML

6118

Figures (1-2)

156

Tables (1-2)

193

Sum=6972

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

894

Download

662

Sum=1556

Oct 7, 2013 (publication date) through Apr 29, 2024

Times Cited of This Article

Times Cited (62)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastroenterol. Oct 7, 2013; 19(37): 6144-6155
Published online Oct 7, 2013. doi: 10.3748/wjg.v19.i37.6144

Table 1 Molecular targets and therapeutic agents

Molecular targets	Therapeutic agents
VEGF/VEGFR	Sorafenib
	Bevacizumab
	Vatalanib (PTK787)
	Cediranib (AZD2171)
	Brivanib
	Sunitinib
	Linifanib (ABT869)
EGF/EGFR	Cetuximab
	Erlotinib
	Lapatinib
IGF/IGFR	OSI-906
	IMC-A12
	AVE1642
	BIIB022
Ras/Raf/MEK/ERK	Sorafenib
Ras/Raf/MEK/ERK	Selumetinib (AZD6244)
PI3K/Akt/mTOR	AZD8055
	Everolimus
	Sirolimus
	Temsirolimus
Wnt-β-catenin	PFK118-310
	PFK115-584
	CGP049090
MET	Tivanitib

EGF: Epidermal growth factor; EGFR: EGF receptor; ERK: Extracellular signal-regulated kinase; FGFR: Fibroblast growth factor receptor; IGFR: Insulin-like growth factor (IGF) receptor; VEGF: Vascular endothelial growth factor; VEGFR: VEGF receptor; mTOR: Mammalian target of rapamycin; MET: Met proto-oncogene.

Citation: Shin JW, Chung YH. Molecular targeted therapy for hepatocellular carcinoma: Current and future. World J Gastroenterol 2013; 19(37): 6144-6155
URL: https://www.wjgnet.com/1007-9327/full/v19/i37/6144.htm
DOI: https://dx.doi.org/10.3748/wjg.v19.i37.6144